BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:51:19 2024-12-13 pm EST			5-day change	1st Jan Change
178.88 ^USD	-0.77%		-12.92%	-0.72%

02:54pm	Sector Update: Health Care	MT
12:07pm	BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy	MT

BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index

June 16, 2024

BeiGene, Ltd Added

Latest news about BeiGene, Ltd.

Sector Update: Health Care	08:54am	MT
BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy	06:07am	MT
Beigene Insider Sold Shares Worth $7,805,106, According to a Recent SEC Filing	Dec. 12	MT
BeiGene Secures $400 Million Facility from China Merchants Bank	Dec. 11	MT
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading	Dec. 10	MT
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	Dec. 09	CI
BeiGene, Ltd. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM	Dec. 05
BeiGene, Ltd. and CLL Society Partner to Advance Test Before Treat? Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	Dec. 04	CI
BeiGene Insider Sold Shares Worth $9,190,570, According to a Recent SEC Filing	Dec. 02	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	Nov. 29	MT
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Hong Kong Stocks End Week in Green; Mokingran Jewellery Gains 8% in Debut	Nov. 29	MT
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%	Nov. 29	MT
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment	Nov. 27	DJ
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	Nov. 27	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data	Nov. 27	MT
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients	Nov. 27	MT
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval	Nov. 27	DJ
European Commission Approves BeiGene?s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	Nov. 27	CI
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK	Nov. 21	DJ
Labcorp Holdings Finance Chief Glenn Eisenberg to Retire	Nov. 19	MT
Labcorp Holdings Inc. Announces Executive Changes	Nov. 19	CI
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Nov. 14	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Powell Speech	Nov. 14	MT

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,600

Sector

Biotechnology & Medical Research

Calendar

2024-12-16 - Business Update Call

More about the company